Back to today’s briefing

Story perspectives

FDA Approves First Non-Opioid Painkiller in 20 Years

2/7/2025

31 6

Summary

Story summary

The FDA has made a groundbreaking decision by approving Journavx (suzetrigine), marking the arrival of the first non-opioid painkiller in two decades. Developed by Vertex Pharmaceuticals, this innovative drug targets the Nav1.8 sodium channel, offering acute pain relief without the threat of addiction. However, its effectiveness for chronic pain still raises questions, emphasizing the ongoing quest for safer pain management solutions.

1 of 1

Story summary

The FDA has made a groundbreaking decision by approving Journavx (suzetrigine), marking the arrival of the first non-opioid painkiller in two decades. Developed by Vertex Pharmaceuticals, this innovative drug targets the Nav1.8 sodium channel, offering acute pain relief without the threat of addiction. However, its effectiveness for chronic pain still raises questions, emphasizing the ongoing quest for safer pain management solutions.